Trust Company’s Corbus Pharmaceuticals CRBP Stock Holding History

Trust Company’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3	Closed	-$1K	–	332
2022 Q1	$1K	Hold	3	–	–	﹤0.01%	332
2021 Q4	$1K	Hold	3	–	–	﹤0.01%	309
2021 Q3	$1K	Hold	3	–	–	﹤0.01%	299
2021 Q2	$1K	Hold	3	–	–	﹤0.01%	299
2021 Q1	$1K	Hold	3	–	–	﹤0.01%	324
2020 Q4	$1K	Hold	3	–	–	﹤0.01%	279
2020 Q3	$1K	Hold	3	–	–	﹤0.01%	307
2020 Q2	$1K	Hold	3	–	–	﹤0.01%	287
2020 Q1	$1K	Hold	3	–	–	﹤0.01%	278
2019 Q4	$1K	Hold	3	–	–	﹤0.01%	279
2019 Q3	$1K	Hold	3	–	–	﹤0.01%	310
2019 Q2	$1K	Hold	3	–	–	﹤0.01%	292
2019 Q1	$1K	Hold	3	–	–	﹤0.01%	321
2018 Q4	$1K	Hold	3	–	–	﹤0.01%	307
2018 Q3	$1K	Hold	3	–	–	﹤0.01%	330
2018 Q2	$1K	Hold	3	–	–	﹤0.01%	345
2018 Q1	$1K	Hold	3	–	–	﹤0.01%	341
2017 Q4	$1K	Hold	3	–	–	﹤0.01%	361
2017 Q3	$1K	Hold	3	–	–	﹤0.01%	299
2017 Q2	$1K	Hold	3	–	–	﹤0.01%	314
2017 Q1	$1K	Buy	+3	New	+$736	﹤0.01%	335

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Trust Company's CRBP Position: Q2 2022 in Review

Trust Company sold out of Corbus Pharmaceuticals (CRBP) in Q2 2022, closing a stake of 3 shares — an estimated $1K sold.

Trust Company first reported a position in CRBP in Q1 2017 and held it in 21 quarters. The position peaked at $1K in Q1 2022. 70 funds tracked by Wall St. Rank hold CRBP as of Q2 2022.

Trust Company reported no remaining Corbus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Trust Company sold 3 Corbus Pharmaceuticals shares in Q2 2022, an estimated $1K.
Trust Company first reported a position in Corbus Pharmaceuticals in Q1 2017 and held it in 21 quarters.
Trust Company's Corbus Pharmaceuticals position peaked at $1K in Q1 2022.
70 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2022.

Based on Trust Company's 13F filing for Q2 2022, filed 6 Jul 2022.